In line with plasmablasts being CD19low-positive and a valid biomarker for IgG4-RD [17], we measured the CD19-positive cell population in some patients before and after RTX therapy and observed a downregulation (data not shown). Here, CD19 is linked to immunoglobulin G4-related sclerosing disease.